Skip to main content

Table 3 Response to treatment

From: Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

 

Total (n)

DL1 (n)

DL2 (n)

DL3 (n)

 

n = 20

n = 7

n = 7

n = 6

Response

    

  Complete Remission

1

1

0

0

  Partial Remission

14

2

6

6

  Stable Disease

3

3

0

0

  Not evaluable

2

1

1

0